- In November 2024, Mitsui Chemicals, Inc. has invested in Rege Nephro Co., Ltd. through the 321FORCE Global Innovation Fund L.P. Rege Nephro, focused on R&D for kidney disease drugs, will benefit from this investment by accelerating the development of its innovative treatments
- In October 2024, Rege Nephro Co., Ltd. has secured approximately USD17 million in new Series B funding, bringing its total funding to USD30 million. The round was led by strategic investors such as DCI Partners Co., Ltd., JIC Venture Growth Investments, and several others. The funds will advance Phase II clinical trials for RN-014, a promising treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and support preclinical trials for RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy. This funding will enable Rege Nephro to accelerate the development of its innovative treatments, bringing them closer to improving outcomes for patients with kidney diseases
- In March 2024, Vertex Pharmaceuticals announced that the U.S. FDA has cleared the IND for VX-407, a first-in-class small molecule corrector targeting the underlying cause of ADPKD in patients with specific PKD1 genetic variants. This approval will help Vertex advance its development of innovative treatments for ADPKD, potentially expanding its pipeline and market presence
- In January 2024, XORTX Therapeutics has submitted a new patent for treating chronic kidney disease (CKD), focusing on safer and more effective oral and sublingual formulations of xanthine oxidase inhibitors (XOI) for conditions such as ADPKD, diabetic nephropathy, and others. This patent will help the company protect its innovative treatment strategies and enhance its portfolio in the kidney disease market
